Partnership unites Illumina’s leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and MyOme, a…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
